Novartis (NVS) announced its mid-term guidance to 2025-2030 of a sales CAGR of 5-6% cc. The company noted that the updated outlook follows upgrade of 2024-2029 guidance to 6% cc. Also, the peak sales guidance was upgraded for Kisqali and Scemblix: Kisqali raised from $8 billion plus to $10 billion plus; Scemblix raised from $3 billion plus to $4 billion plus. Novartis expects 15 plus potentially submission-enabling readouts over the next two years.
Novartis said its delivered a core operating income margin of 41.2% in the first nine months of 2025 - two years ahead of plan - and expects to return to 40% plus margins by 2029, after absorbing 1-2 percentage points of dilution from the planned acquisition of Avidity Biosciences, which is expected to close in the first half of 2026.
Vas Narasimhan, CEO of Novartis, said: "Over the past two years, we have executed more than 30 strategic deals, bolstering our pipeline and strengthening the outlook of the business in the mid-2030s and beyond."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.